Antibody that binds to LY6G6D
Antibodies targeting LY6G6D with defined CDR sequences address the challenge of treating chemotherapy-resistant colorectal cancer by enhancing therapeutic responses through specific binding and cellular activation.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- キューエルエスエフバイオセラピューティクスインコーポレイテッド
- Filing Date
- 2024-04-05
- Publication Date
- 2026-06-26
AI Technical Summary
Current treatments for colorectal cancer, particularly in patients resistant to chemotherapy or immune checkpoint therapy, lack effective targets due to low expression of LY6G6D in other tumor types and normal cells, limiting the efficacy of existing therapies.
Development of antibodies that specifically bind to LY6G6D, utilizing defined CDR sequences for the heavy and light chain variable regions, which can be monospecific or bispecific, including modifications for enhanced functionality such as FcRn binding mutations and silencing mutations, for targeted treatment of colorectal cancer.
The antibodies effectively target LY6G6D-expressing colorectal cancer cells, enhancing therapeutic responses in chemotherapy-resistant patients by inducing cellular events like cytokine release and cytotoxicity, demonstrating antitumor effects in preclinical models.
Smart Images
Figure 2026521103000001_ABST